What is Voage V Tablet 15 used for?

Voage V Tablet 15 is used to manage type 2 diabetes along with diet and exercise, reduce kidney disease risk, and lower the chance of cardiovascular death.

How does Voage V Tablet 15 work?

It contains dapagliflozin and vildagliptin, which work together to control blood sugar levels. Dapagliflozin eliminates excess sugar from the body through urine, while vildagliptin increases insulin production.

How should I take Voage V Tablet 15?

You should take your Voage V Tablet 15 as per your doctor's prescription. It can be taken with or without food. The tablet should be swallowed whole, not split, crushed, or chewed.

What are the side effects of Voage V Tablet 15?

Common side effects include hypoglycaemia (low blood sugar), genital yeast infections, urinary tract infections, nausea, diarrhoea, abdominal discomfort, and increased urination.

Who should not take Voage V Tablet 15?

Avoid taking Voage V Tablet 15 if you have an allergy to dapagliflozin or vildagliptin, severe kidney disease, metabolic acidosis including diabetic ketoacidosis or type 1 diabetes.

Can I take other medicines while using Voage V Tablet 15?

Some medicines may interact with Voage V Tablet 15 like loop diuretics and insulin. It is always best to consult your doctor before starting any new medication.

What should I do if I overdose on Voage V Tablet 15?

In case of an overdosage on Voage V Tablet 15, seek immediate medical attention. Both dapagliflozin and vildagliptin are dialyzable, meaning they can be removed from the body through dialysis.

Voage V 10/100 MG | Order Voage V 10/100 MG Tablet Online at Truemeds

undefined

Voage V Tablet 15 is used to manage type 2 diabetes. It combines dapagliflozin and vildagliptin to control blood sugar levels effectively. It works by improving insulin sensitivity and reducing glucose production. This combination medicine belongs to the class of antidiabetic medications.

In addition to its main use, this medicine also helps mitigate the risk of cardiovascular death and hospitalisation due to heart failure. It assists in treating chronic kidney disease associated with type 2 diabetes, thereby contributing to improved overall health outcomes.

Before you start taking this medicine, it's crucial to consult your doctor, who will prescribe the right dosage and frequency based on your medical condition. Inform your doctor about any pre-existing health issues or other medicines you are currently taking. If you notice any side effects while on this medication, immediately report to your doctor. Remember to continue this medicine for the duration prescribed by your doctor for optimal results.

National Health Service. (n.d.). Dapagliflozin (Forxiga). Retrieved 1 April 2024, from https://www.nhs.uk/medicines/dapagliflozin/how-and-when-to-take-dapagliflozin/
Li, J., Gong, Y., Li, C., Lu, Y., Liu, Y., Shao, Y., ... & Liu, L. (2022). Efficacy and safety of dapagliflozin in patients with type 2 diabetes: A meta-analysis of randomized controlled trials. Journal of Diabetes Research, 2022. Retrieved 1 April 2024, from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10291938/
U.S. Food and Drug Administration. (2014). FDA approval letter - FARXIGA. Retrieved 1 April 2024, from https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2014/205649Orig1s000ltr.pdf
Gautam, K., Tripathy, R., Meher, D., & Sahoo, J. P. (2023). Dapagliflozin versus vildagliptin as an adjuvant to metformin in patients with type 2 diabetes mellitus: A randomized, open-label study. Cureus, 15(4), e38200. https://doi.org/10.7759/cureus.38200
Albarrán, O. G., & Ampudia-Blasco, F. J. (2013). [Dapagliflozin, the first SGLT-2 inhibitor in the treatment of type 2 diabetes]. Medicina Clinica, 141 Suppl 2, 36–43. https://doi.org/10.1016/S0025-7753(13)70062-9
Wang, L.-G., Wang, H., Liu, Q., Hua, W.-C., & Li, C.-M. (2017). A network meta-analysis for efficacy and safety of seven regimens in the treatment of type II diabetes. Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie, 92, 707–719. https://doi.org/10.1016/j.biopha.2017.05.002